1093.0000 -10.30 (-0.93%)
NSE Sep 23, 2025 15:31 PM
Volume: 28,220
 

1093.00
-0.93%
ICICI Securities Limited
Tatva Chintan Pharma Chem’s (TATVA) revenue grew 7.3% QoQ, but gross profit margin collapsed to just 45.9% (vs 57.8% in Q4FY24) due to high-cost inventory, particularly in SDA, where it had to take 15-20% price.
Tatva Chintan Pharma Chem Ltd. has gained 55.54% in the last 6 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended